Approximately 10% of GIST patients have primary resistance to imatinib and many of these resistant tumors lack mutations in KIT or PDGFRA, or they harbor a PDGFRA exon 18 D842V mutation. The gene discussed is KIT; the disease is gastrointestinal stromal tumor.